Gan & Lee Pharmaceuticals Co Ltd
Gan & Lee Pharmaceuticals., a biopharmaceutical company, engages in the research, development, production, and sale of insulin analog active pharmaceutical ingredients (APIs) and injections in China. Its products include Basalin, an insulin glargine injection; Prandilin, an insulin lispro injection; Prandilin 25, an insulin lispro mix 75/25 injection; Rapilin, an insulin aspart injection; Rapilin… Read more
Gan & Lee Pharmaceuticals Co Ltd (603087) - Total Assets
Latest total assets as of September 2025: CN¥12.14 Billion CNY
Based on the latest financial reports, Gan & Lee Pharmaceuticals Co Ltd (603087) holds total assets worth CN¥12.14 Billion CNY as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Gan & Lee Pharmaceuticals Co Ltd - Total Assets Trend (2013–2024)
This chart illustrates how Gan & Lee Pharmaceuticals Co Ltd’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Gan & Lee Pharmaceuticals Co Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
Gan & Lee Pharmaceuticals Co Ltd's total assets of CN¥12.14 Billion consist of 31.5% current assets and 68.5% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 7.5% |
| Accounts Receivable | CN¥248.57 Million | 2.1% |
| Inventory | CN¥1.05 Billion | 8.7% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥1.19 Billion | 9.9% |
| Goodwill | CN¥0.00 | 0.0% |
Asset Composition Trend (2013–2024)
This chart illustrates how Gan & Lee Pharmaceuticals Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Gan & Lee Pharmaceuticals Co Ltd's current assets represent 31.5% of total assets in 2024, a decrease from 60.7% in 2013.
- Cash Position: Cash and equivalents constituted 7.5% of total assets in 2024, down from 27.9% in 2013.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 9.0% of total assets, a decrease from 20.0% in 2013.
- Asset Diversification: The largest asset category is intangible assets at 9.9% of total assets.
Gan & Lee Pharmaceuticals Co Ltd Competitors by Total Assets
Key competitors of Gan & Lee Pharmaceuticals Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Beijing Centergate Technologies Holding Co Ltd
SHE:000931
|
China | CN¥3.82 Billion |
|
Blue Sail Medical Co Ltd
SHE:002382
|
China | CN¥16.46 Billion |
|
Andon Health Co Ltd
SHE:002432
|
China | CN¥28.98 Billion |
|
Allmed Medical Products Co Ltd Class A
SHE:002950
|
China | CN¥5.35 Billion |
|
Inix Technologies Holdings Bhd
KLSE:0094
|
Malaysia | RM72.53 Million |
|
Focus Point Holdings Bhd
KLSE:0157
|
Malaysia | RM328.19 Million |
|
Careplus Group Bhd
KLSE:0163
|
Malaysia | RM286.61 Million |
|
LKL International Bhd
KLSE:0182
|
Malaysia | RM173.46 Million |
Gan & Lee Pharmaceuticals Co Ltd - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Gan & Lee Pharmaceuticals Co Ltd generates 0.25x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Solid ROA - For every $100 in assets, Gan & Lee Pharmaceuticals Co Ltd generates $5.10 in net profit.
Gan & Lee Pharmaceuticals Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 7.20 | 8.04 | 14.54 |
| Quick Ratio | 5.57 | 6.77 | 13.34 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥4.28 Billion | CN¥ 5.68 Billion | CN¥ 5.55 Billion |
Gan & Lee Pharmaceuticals Co Ltd - Advanced Valuation Insights
This section examines the relationship between Gan & Lee Pharmaceuticals Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.32 |
| Latest Market Cap to Assets Ratio | 0.22 |
| Asset Growth Rate (YoY) | 2.8% |
| Total Assets | CN¥12.04 Billion |
| Market Capitalization | $2.68 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Gan & Lee Pharmaceuticals Co Ltd's assets below their book value (0.22 x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Gan & Lee Pharmaceuticals Co Ltd's assets grew by 2.8% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Gan & Lee Pharmaceuticals Co Ltd (2013–2024)
The table below shows the annual total assets of Gan & Lee Pharmaceuticals Co Ltd from 2013 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥12.04 Billion | +2.80% |
| 2023-12-31 | CN¥11.72 Billion | +10.45% |
| 2022-12-31 | CN¥10.61 Billion | -2.27% |
| 2021-12-31 | CN¥10.85 Billion | +14.15% |
| 2020-12-31 | CN¥9.51 Billion | +57.76% |
| 2019-12-31 | CN¥6.03 Billion | +28.37% |
| 2018-12-31 | CN¥4.69 Billion | +25.42% |
| 2017-12-31 | CN¥3.74 Billion | +43.76% |
| 2016-12-31 | CN¥2.60 Billion | +43.77% |
| 2015-12-31 | CN¥1.81 Billion | +50.62% |
| 2014-12-31 | CN¥1.20 Billion | +44.43% |
| 2013-12-31 | CN¥832.55 Million | -- |